Author

I. T. Hentenaar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

F. E.-H. Lee· 2 shared A. Moreno· 1 shared A. Porter-Morrison· 1 shared B. A. Pinsky· 1 shared B. Wali· 1 shared C. Saney· 1 shared D. C. Douek· 1 shared D. C. Nguyen· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

F. E.-H. Lee

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintSep 10, 2023

Majority of human circulating plasmablasts stop blasting: A probable misnomer

D. C. Nguyen, C. Saney, I. T. Hentenaar…·F. E.-H. Lee

The study shows most blood plasmablasts are not actively dividing, suggesting the term 'plasmablast' may be misleading.

DOI 10.1101/2023.09.10.557057

humanflow cytometry

𝕏 PostBluesky

ImmunologybioRxivPreprintOct 31, 2022

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

M. E. Davis-Gardner, L. Lai, B. Wali…·M. S. Suthar

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

DOI 10.1101/2022.10.31.514636

humanexperimental assay

𝕏 PostBluesky